Topic: autoimmune disease
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.
China’s Jacobio Pharmaceuticals raised $55 million to advance a cancer drug into the clinic, conduct preclinical work and ramp up its R&D pipelines.
AstraZeneca’s anifrolumab for lupus has missed the target in the first of two ongoing phase 3 trials, putting its future in doubt.
Principia Biopharma has filed to raise up to $86.3 million in its IPO to carry its lead BTK inhibitor into phase 3.
Brand-new U.K. biotech Izana has kicked off a phase 2a trial of anti-GM-CSF antibody namilumab in ankylosing spondylitis.
Blocking the signaling receptor NLRP3 could treat a range of autoimmune disorders, IFM researchers believe.
The agreement tasks Tsinghua with discovering cancer and autoimmune disease therapeutics that Bristol-Myers can then choose to license.